Fda has janson TREMFYA ® One-Press for treatment of moderate to severe plaque psoriasis

recently http://
, the U.SFDA(http://has approved the company's TREMFYA ® One-Press, a one-time, single-dose patient self-controlled syringe for the treatment of moderate to severe plaque psoriasis,at the http://companyon the tREMFYA ®TREMFYA ® is the first FDA-approvedto provide a patient-controlled injectiondrug(http://A single press is designed according to the patient's idea: it is comfortably placed on the hand, the injection can be controlled, and the needle is hidden throughout the processTREMFYA 100mg subcutaneous injections are used every 8 weeks after the starting injection in weeks 0 and 4TREMFYA is required under the guidance and supervision of a physician, but patients may perform TREMFYA One-Press injections on their own with the approval and appropriate training of the doctorThe self-controlled injection forms are already available in the United StatesThe ORION double-blind, placebo-controlled study also evaluated the efficacy and safety of tREMFYA (guselkumab) one-time pressure injection for treatment in patients with moderate to severe plaque psoriasis in this study, a higher percentage of patients in the TREMFYA group achieved an IGA score or PASI90 response of 0 or 1 in week 16 (81% and 76%, respectively), while the placebo group had a 0% endpoint In the TREMFYA group, the proportion of patients who achieved an IGA score of 0 in week 16 was higher than in the placebo group (56 percent vs.0%) in the TREMFYA group, the proportion of patients who received a PASI100 response at week 16 was higher than in the placebo group (50 percent vs.0 percent) Most of the reaction symptoms at the injection site of a single press injection are mild and transient in nature 　　The one-press design allows the patient to control the speed and pressure of the injection Clicking indicates when the administration is complete, ensuring that nearly 99% of patients successfully complete their first injection The one-time press also includes a safety system to protect the safety of the needle after use After three injections, patients still reported good availability of the one-press device